High blood pressure (BP) is a major risk factor for coronary heart disease, heart failure, stroke, chronic kidney disease, end stage renal disease, and a variety of other clinically important outcomes. [1] [2] [3] [4] Results from the surveys described in this issue and elsewhere 5 underscore a common finding that hypertension is both highly prevalent and insufficiently treated and controlled. Recognizing the differences in sampling and survey measurement techniques, the reported prevalence of hypertension (SBP/DBP Z140/90 mmHg or treatment with antihypertensive medication) in adults exceeded 25% in all of the surveys reported in this issue. In Latvia, the prevalence of hypertension for 25-64-yearold adults in the general population was 46.1%. 6 Control of hypertension with medication to an SBP/DBP o140/ 90 mmHg in the general population ranged from as low as 12% to a high of only 29%. [7] [8] [9] Data from other parts of the world provide an equally distressing picture of what is (not) being accomplished in treatment and control of hypertension at the level of the general population. 5, 10, 11 These data provide testimony to an urgent need for greater attention to the treatment and control of hypertension in populations around the world. This was the basis for a panel discussion at the International Society of Hypertension satellite conference The Epidemiology of Hypertension-Regional Differences in Treatment and Control. Panel participants included Drs P Whelton, S Sonkodi, DG Beevers, JG Fodor, H Elliot, R Cifkova, A Nissinen, A Javor, and there was active participation of other symposium attendees. The following summarizes key elements of the discussion and recommendations of the panel. recently explored factors associated with awareness of hypertension in a representative sample of 15 838 adults in China. 12 Higher awareness of hypertension was noted in those who were married and had their BP measured during the 5 years (especially the 1 year) preceding the study. Men and current smokers were less aware of their diagnosis. In settings where there is limited contact with the health care community, mass screening provides a useful approach to increase awareness of the diagnosis. Such screening should, however, be closely linked to diagnostic and treatment opportunities. In most industrialized societies adults come in contact with the health care community and have their BP measured on a relatively frequent basis. 13, 14 Under this circumstance, the challenge is to ensure communication of the diagnosis in a fashion that the individual with hypertension can comprehend.
Treatment and control
Factors associated with treatment and control of hypertension have been explored in at least three population studies. In an analysis of 1103 untreated Framingham Heart Study participants, Lloyd-Jones et al.
15 identified a positive relationship between level of BP, cardiovascular disease and left ventricular hypertrophy and treatment of hypertension. Control of hypertension (antihypertensive medication with an SBP/DBP o140/90 mmHg) was inversely related to level of BP and age. He et al. 16 took advantage of the large size and representative nature of the Third US National Health and Nutrition Examination Survey (NHANES) to investigate hypertension treatment and control relationships in 5886 US adults. They found higher rates of control in women compared to men, and in non-Hispanic whites and blacks compared to Mexican-Americans. Non-Hispanic white women were the best (28.7%) and Mexican-American men the least well (12.7%) controlled. The odds ratio (OR; 95% confidence interval (CI)) for control of hypertension was substantially better in those who were currently (2.39, 1.52-3.74) or formerly (1.81, 1.12-2.93) married, had private health insurance (1.59, 1.02-2.49), visited the same facility for their health care (2.77, 1.88-4.09), saw the same provider for their health care (2.29, 1.74-3.02), had their BP measured during the preceding 6 months (8.00, 3.75-17.1) or 6-11 months (5.31, 2.51-11.2), and reported using lifestyle modification to control their hypertension (6.02, 4.20-8.63 ). In the previously mentioned survey of 15 838 Chinese adults, gender, socioeconomic, and lifestyle factors were also found to be associated with both treatment and control of hypertension. 12 The OR, 95% CI for treatment in men compared to women was 0.76, 0.59-0.98, and was 2.06, 1.38-3.15 for those in the highest compared to the lowest quartile of income. Compared to all others, the OR and 95% CI for those who had their BP measured during the proceeding 12 months was 3.86 and 1.83-8.61. Control of hypertension was also more common in participants whose BP had been measured during the preceding year (OR, 95% CI; 4.93, 1.51-16.1) or 1-5 years (14.8, 3.63-60.5), and in those who were engaged in lifestyle modification (1.57, 1.15-2.16). In an analysis of 33 357 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), control of hypertension increased steadily from 27.4% at baseline to 66% after 5 years of follow-up. Control rates varied significantly by geographic regions, practice settings, and demographic and clinical characteristics of the participants.
The epidemiologic data provide abundant evidence of the need for increasing awareness, and improving treatment and control of hypertension. In practice settings such as those that prevailed in the ALLHAT, where participants' treatment was carefully supervised and medications were provided, far better rates of hypertension control have been achieved than those seen in most national surveys. The data from NHANES and InterASIA strongly underscore the importance of a regular source of health care, social reinforcement, and attention to lifestyle factors in increasing hypertension treatment and control rates. Education of the general population using simple, action-oriented messages that identify the risks of untreated hypertension, the benefits and ease of appropriate treatment, and the positive consequences of a healthy lifestyle provide an important underpinning for efforts by health care professionals in practice settings aimed at improving treatment and control of hypertension. The level of attention given to hypertension treatment, and control by health care professionals appears to be influenced by knowledge, ease of treatment, practice guidelines, social norms, reimbursement, and other nonmonitory rewards. Professional societies, international agencies, government agencies, and the pharmaceutical industry have important roles in setting policies and in pricing that impact awareness and ease of treatment. To this point, most governments and nongovernmental agencies have paid insufficient attention to ensuring that we translate our abundant knowledge from observational and therapeutic research investigations to the practice of hypertension prevention, detection, treatment, and control. There seems little doubt that greater attention and an enhanced commitment of resources would result in a doubling or tripling of treatment and control rates. The time has come to take a more active stance.
